Literature DB >> 22507343

Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: a single centre experience.

A Gigante, C Salviani, K Giannakakis, E Rosato, B Barbano, A Moroso, M L Gasperini, I Nofroni, F Salsano, R Cianci, F Pugliese.   

Abstract

Renal-limited vasculitis is a pauci-immune crescentic glomerulonephritis with no signs of systemic involvement, representing one of the most common causes of rapidly progressive glomerulonephritis. The study aims to examine clinical and histological features in twenty-four patients with RLV diagnosed by the Nephrology Department of Sapienza University of Rome, Italy, evaluating the role of these parameters in predicting renal survival. Patients details, clinical and histological features and outcomes were recorded at the time of renal biopsy and over a mean follow-up period of 36±6 months. In our study, serum creatinine at presentation was significantly higher in patients who had a poor outcome than in those who survived with independent renal function (6.3±2.47 mg/dl vs 2.84±2.01 mg/dl, P= 0.002). The presence of C3c was found in the area of glomerular fibrinoid necrosis and in small arteries and arterioles with fibrinoid necrosis in 17 patients (P= 0.018). In conclusion, serum creatinine at presentation and focal C3c depositions in areas of glomerular and arteriolar fibrinoid necrosis were the best determinants of poor renal outcome, maybe underlining the pathogenic role of alternative pathway activation of complement system but also demonstrating the focal distribution of necrotizing lesions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507343     DOI: 10.1177/039463201202500133

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  7 in total

1.  C5a receptor (CD88) blockade protects against MPO-ANCA GN.

Authors:  Hong Xiao; Daniel J Dairaghi; Jay P Powers; Linda S Ertl; Trageen Baumgart; Yu Wang; Lisa C Seitz; Mark E T Penfold; Lin Gan; Peiqi Hu; Bao Lu; Norma P Gerard; Craig Gerard; Thomas J Schall; Juan C Jaen; Ronald J Falk; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

Review 2.  Complement in ANCA-associated vasculitis.

Authors:  J Charles Jennette; Hong Xiao; Peiqi Hu
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

3.  Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome.

Authors:  Godasi S R S N K Naidu; Aman Sharma; Ritambra Nada; Harbir Singh Kohli; Vivekanand Jha; Krishan Lal Gupta; Vinay Sakhuja; Manish Rathi
Journal:  Rheumatol Int       Date:  2014-05-18       Impact factor: 2.631

Review 4.  Localized Forms of Vasculitis.

Authors:  Joana Martins-Martinho; Eduardo Dourado; Nikita Khmelinskii; Pablo Espinosa; Cristina Ponte
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

5.  Clinicopathological Characteristics and Outcomes of Diffuse Crescentic Glomerulonephritis - A Single Center Experience from Southern India.

Authors:  Shankar Prasad Nagaraju; Sindhura Lakshmi Koulmane Laxminarayana; Srinivas Kosuru; Rajeevalochana Parthasarathy; Ravindra Prabhu Attur; Dharshan Rangaswamy; Uday Venkat Matteti; Vasudeva Guddattu
Journal:  J Clin Diagn Res       Date:  2017-09-01

6.  Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Authors:  Takashi Iwakiri; Shouichi Fujimoto; Kiyoki Kitagawa; Kengo Furuichi; Junya Yamahana; Yunosuke Matsuura; Atsushi Yamashita; Shigehiro Uezono; Yoshiya Shimao; Shuichi Hisanaga; Takeshi Tokura; Takashi Wada; Kazuo Kitamura; Yujiro Asada
Journal:  BMC Nephrol       Date:  2013-06-17       Impact factor: 2.388

7.  Clinical spectrum and outcomes of crescentic glomerulonephritis: A single center experience.

Authors:  S K Rampelli; N G Rajesh; B H Srinivas; K T Harichandra Kumar; R P Swaminathan; P S Priyamvada
Journal:  Indian J Nephrol       Date:  2016 Jul-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.